Irish-listed speciality drug firm Amryt Pharma has agreed a €20m loan facility from the European Investment Bank, which will provide it with near- and mid-term funding requirements for its lead product, Episalvan.

Amryt Pharma has been granted a US patent for its lead drug to be used as a treatment in the lucrative orphan disease market.